Register Login

Bleeding Disorders

September 2024 Quick Question: PTT

I (Geo) prefer PTT to APTT or aPTT because the “A” or “a” is superfluous.  Laboratory scientists no longer offer an “unactivated” PTT. The “partial thromboplastin” reagent consists of a phospholipid or combination of phospholipids that may include animal, plant, or synthetic sourced phosphatidylserine, phosphatidylcholine, phosphatidylinositol, sphingomyelin, and/or phosphatidylethanolamine. Accompanying the phospholipid is one of […]
read more

August 2024 Quick Question Summary: Rebalancing Therapy

Our August 2024 Quick Question, which attracted 18 responses, asked, “Which hemophilia ‘rebalancing’ therapy suppresses antithrombin RNA production?” Here are your answers: Efanesoctocog alfa: 0 Concizumab: 3 (17%) Octavian 2 (11%) Hemgenix 3 (17%) Fitusiran 10 (55%) Rebalancing therapy is the name for using RNA inhibitors (RNAi) that suppress mRNA synthesis, subsequently suppressing selected molecules. […]
read more

Extended Life Cryoprecipitate Fibrinogen

As reported by Amy Carpenter quoting Jay Hudgins, DO, MS, director of hemostasis and thrombosis, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio, USA in the August 2024 edition of CAP Today, extended-life cryoprecipitate has several applications. INTERCEPT®, is the Cerus, Inc. trademark for their materials that crosslink and inactivate bacterial and […]
read more